Alpha-GalCer (KRN7000) used in dendritic research

KRN7000 applied to dendritic cells research

Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity

Comparison of clinical and immunological effects of intravenous and intradermal administration of {alpha}-GalactosylCeramide (KRN7000) - pulsed dendritic cells

Administration of {alpha}-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo

DC therapy induces long-term NK reactivity to tumors via host DC

Exploiting the Role of Endogenous Lymphoid-Resident Dendritic Cells in the Priming of NKT Cells and CD8+ T Cells to Dendritic Cell-Based Vaccines

The in vitro proliferation and cytokine production of Vα24+Vβ11+ natural killer T cells in patients with systemic lupus erythematosus

α-Galactosylceramide activates antitumor immunity against liver tumor

Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand

Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells

Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function

Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein

Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells

Invariant NKT Cells Preferentially Modulate the Function of CD8 α ⁺ Dendritic Cell Subset in Inducing Type 1 Immunity against Infection

Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy

Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice

Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo

Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells

Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells

Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients

A Phase I Study of Alpha-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer

Dendritic cell maturation by CD11c^- T cells and Vα24⁺ NKT cell activation by α-Galactosylceramide

Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment

Cutting Edge: Inhibition of Experimental Tumor Metastasis by Dendritic Cells Pulsed with alpha-Galactosylceramide

Natural Killer T Cell–Based Cancer Immunotherapy

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients

Cytokine-Dependent Modificatino of IL-12p70 and IL-23 Balance in Dendritic Cells by Ligand Activation of Vα24 Invariant NKT Cells

The Natural Killer T (NKT) Cell Ligand alpha-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells

NKT Cells Enhance CD4⁺ and CD8⁺ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells

Ligand-dependent induction of noninflammatory dendritic cells by anergic invariant NKT cells minimizes autoimmune inflammation

Efficient activation of Valpha14 invariant NKT cells by foreign lipid antigen is associated with concurrent dendritic cell-specific self recognition

Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor

Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells

Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells

Therapeutic activation of V alpha 24(+)V beta 11(+) NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs

Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets

Active immunization against cancer with dendritic cells: The near future

NKT Cells Immunotherapy: Targeting Dendritic Cells with Glycolipid Liposomes

Immunization with dendritic cells loaded with alpha-galactosylceramide at priming phase, but not at boosting phase, enhances cytotoxic T lymphocyte activity against infection by intracellular bacteria

Ligand-dependent induction of noninflammatory dendritic cells by anergic invariant NKT cells minimizes autoimmune inflammation

NKT cell ligand alpha-galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation

Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner

Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity

The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation

Tumor-infiltrating effector cells of alpha-galactosylceramide-induced antitumor immunity in metastatic liver tumor

Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles

Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells

Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells

Gene expression analysis in human monocytes, monocyte-derived dendritic cells, and alpha-galactosylceramide-pulsed monocyte-derived dendritic cells

Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer

Acidification-dependent activation of CD1d-restricted natural killer T cells is intact in cystic fibrosis

Natural killer T cells are critical for dendritic cells to induce immunity in Chlamydial pneumonia

Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs

Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells

Induction of active antitumor immune response by myeloma idiotype protein-pulsed dendritic cells

Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients